From CSRxP <[email protected]>
Subject Big Pharma Earnings Watch: AstraZeneca
Date November 11, 2025 4:00 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
Major Drug Company Surpasses Wall Street Forecasts as Price Hikes Fuel Growth









BIG PHARMA EARNINGS WATCH: ASTRAZENECA

Major Drug Company Surpasses Wall Street Forecasts as Price Hikes Fuel Growth



This past week, Big Pharma company AstraZeneca reported third quarter earnings
that beat Wall Street expectations — continuing a trend among major drug
manufacturers posting strong profits on the heels of continuing to hike
prescription drug prices this year.



AstraZeneca

* AstraZeneca reported quarterly revenue expectations, beating Wall Street
analysts’ expectations
<[link removed]>
.
* The Big Pharma giant affirmed its commitment to reaching $80 billion
<[link removed]>
in annual revenue by 2030.
* AstraZeneca’s total revenue increased to $15.19 billion
<[link removed]>
, boosted by its oncology and biopharmaceutical segments.
* The company’s cancer-medicine portfolio saw revenue of $6.64 billion
<[link removed]>
, fueled by blockbuster drugs Tagrisso and Imfinzi, which brought in$1.86
billion and $1.6 billion
<[link removed]>
, respectively.
This strong earnings report underscores the company’s continued reliance on
price hikes on its blockbuster drugs to drive revenue growth.



AstraZeneca

* AstraZeneca has hiked prices on 22 prescription drugs
<[link removed]> so far in 2025, including
diabetes drug Farxiga bythree percent
<[link removed]> and Lokelma by five percent
<[link removed]>.
* AstraZeneca increased prices on 17 prescription drugs
<[link removed]> to start off 2024, including
oncology drugs Tagrisso and Lynparza by three percent each.
* AstraZeneca hiked prices on at least 25 prescription drugs
<[link removed]> in 2023, including best-selling
oncology drugs Tagrisso by three percent and Lynparza by 6.8 percent.
Read more on expectation-beating third quarter earnings from Johnson & Johnson
HERE <[link removed]>.



Read more on GSK, Merck, Bristol Myers Squibb, Eli Lilly and Gilead’s third
quarter earningsHERE
<[link removed]>
.



Read more on third quarter earnings from AbbVie, Amgen and Pfizer HERE
<[link removed]>.



Learn more about solutions to lower prescription drug prices and hold Big
Pharma accountableHERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>
Screenshot of the email generated on import

Message Analysis

  • Sender: n/a
  • Political Party: n/a
  • Country: n/a
  • State/Locality: n/a
  • Office: n/a
  • Email Providers:
    • Iterable